NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
During 2018, BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT) has attained topline safety and efficacy clinical data in a clinical trial, achieved proof of concept and advanced its BriaCell clinical program. A recent article further discussing the important milestones the company has reached reads, “BriaCell recently announced excellent safety and efficacy data from a phase I/IIa proof of concept clinical study in advanced breast cancer patients. There were reports of tumor shrinkage in various sites. These results were confirming the findings from two previous proof-of-concept clinical trials that showed promising results in patients with advanced breast cancer. The most notable result was observed in a patient whose breast cancer had metastasized. The patient responded to Bria-IMT, and substantial tumor shrinkage occurred. Shrinkage was observed in the breast, lungs, soft tissues and brain.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer